There is a growing risk that malaria parasites will develop resistance to artemisinin because almost half of both its manufacturers and malaria-affected countries are failing to comply with World Health Organization (WHO) demands to sell it only in combination with other drugs. Artemisinin and its derivatives are the leading treatments for the disease, being the only antimalarials that have not yet seen widespread resistance in malaria parasites.
The full scale of the problem is revealed in a soon-to-be-published WHO briefing seen by Nature, "Stop the marketing of oral artemisinin monotherapies", which calls for governments to empower national drug-regulatory authorities to clamp down on offending companies.
Treatments that use only artemisinin need to be taken for seven days to kill all parasites, but patients often stop treatment after a few days when they begin to feel much better. This leaves the remaining parasites in contact with low levels of the drug -a recipe for resistance. The WHO recommended in January 2006 that artemisinin should always be given in combination with other drugs for at least three days, because a cocktail reduces the chances of resistance. The need to move away from monotherapies has become all the more urgent with recent reports of resistance arising in Cambodia.
Although artemisinin-based combination therapies (ACTs) have become the treatment of choice for malaria, with a three-day programme curing more than 95% of patients, monotherapies are cheaper to produce and sell.
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Malaria drug-makers ignore WHO ban
As Francis Collins prepares to take the helm of the US National Institutes of Health (NIH), opinions are divided about how the geneticist will steer the agency through its extraordinary funding boom.
Following President Barack Obama's longanticipated nomination of Collins on 8 July, Harold Varmus, NIH director from 1993 to 1999, and now president and chief executive of the Memorial Sloan-Kettering Cancer Center in New York, described him as "a terrific scientist, inspirational leader, superb manager, and adept politician. I have great confidence in his ability to lead the NIH in complicated times. "
But some believe that Collins has focused too much on genomics to the detriment of other approaches to improving health. Collins directed the NIH's National Human Genome Research Institute (NHGRI) for 15 years until 2008, led the public effort to sequence the human genome and was a co-discoverer of the gene responsible for cystic fibrosis (see Nature 460, 164-169; 2009 ). "The genetic approach is extremely important, but it is a tool, it is not the be all and end all, " says Fran Visco, president of the Washington-based National Breast Cancer Coalition, which has called on the NIH to back more research on the environmental causes of breast cancer.
There are also concerns about whether Collins's very public expressions of his evangelical Christian faith will affect his job. He laid out his beliefs in a 2006 book, The Language of God: A Scientist Presents Evidence for Belief, and last year founded the BioLogos Foundation, which aims to help Christians integrate their faith with contemporary science.
Steven Pinker, a psychologist at Harvard University, says he has "serious misgivings" about the nomination. "Collins is an advocate of profoundly anti-science beliefs, and it is reasonable for the scientific community to ask him how these beliefs will affect his administration of the NIH and his efforts on behalf of the scientific enterprise. "
Several scientists close to Collins say that his faith will not affect his NIH duties. "In all the years that I worked with Francis -and there were a lot of years -I never once saw evidence where his religious faith was in conflict with his scientific judgement, " says developmental biologist Shirley Tilghman, president of Princeton University in New Jersey, who sat on Collins's advisory council when he directed the NHGRI.
"We would count him as an ally, " adds Joshua Rosenau, a policy analyst at the National Center for Science Education, a non-profit organization in Oakland, California, that defends the teaching of evolution in schools. "It is helpful to have scientists like Francis Collins speaking out about how they personally reconcile science and religion. "
The BioLogos Foundation has confirmed that Collins would step down from his role there before taking up the reins at the NIH. It's the right move, says Varmus. "Discussion about the foundation and his involvement with it could readily become a distraction from the business of running the NIH, " he told Nature.
NIH nominee draws scrutiny
Francis Collins is likely to face funding challenges -and criticism of his Christian evangelism.
Francis Collins has been a staunch advocate of genomic medicine.
BUENOS AIRES
Argentina's government has for more than two weeks ignored recommendations from a committee of influenza experts to declare a national health emergency. Although scientists inside the country say they are being ignored, those outside are worried by reports of panicked Argentines travelling to Chile and Uruguay to buy flu drugs. The drugs, which are being taken without medical advice, are probably being used in a way that promotes the development of resistance, says Eric Toner, a senior associate at the University of Pittsburgh's Center for Biosecurity in Pennsylvania. Because Uruguay is heavily dependent on trade with Argentina, it is highly unlikely to prevent Argentines from entering the country -but the governments of Brazil and Bolivia are considering closing their borders to prevent the spread of infection.
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Flu furore hits Argentina
Collins takes over an NIH awash with cash, yet bracing for leaner times after a one-time bolus of US$10.4 billion in economic stimulus spending runs out in September 2010. Spending the money both rationally and quickly is already proving a daunting challenge for the NIH -the world's largest funder of biomedical research -whose peer-review system is close to being overwhelmed by a flood of applications (see Nature 459, 763; 2009). "Every body and their brother is going to have an idea of how to do this, " says Tilghman. "He's going to have to sift through all those ideas and plans and ultimately do what is best for the United States. And he is going to have to do it relatively quickly. " Since Obama's 2010 budget requested only a 1.4% increase for the $30.3-billion agency, the NIH could also face the kind of boom and bust it confronted in 2003, when its rapidly expanded ranks of scientists were left competing for slices of a suddenly very finite pie. "He's going to have to fight for budget, " says Paul Nurse, the Nobelprizewinning biologist who is president of the Rockefeller University in New York.
The NIH is a behemoth that now has 27 institutes and centres and about 18,000 employees -much larger than the more focused NHGRI. "A big challenge for him is going to be to shift into a new role from his old role, " says Elias Zerhouni, who left the NIH director's job last October. "You can't just dictate what you think is right. You have to listen a lot more. "
White House rules prevent Collins from speaking to journalists before his nomination is considered by the Senate Committee on Health, Education, Labor, and Pensions, chaired by Senator Edward Kennedy (Democrat, Massachusetts). Kennedy has called the choice of Collins "inspired", and said he would work to see that the nomination is approved "without delay". ■ Meredith Wadman and fax requests for information, says Andrea Bosman, an official at the WHO's Global Malaria Programme (see http://tinyurl.com/m4gqmn).
Regulatory authorities in just 39 of the 76 countries using malaria drugs have so far complied or said they intend to comply with the WHO's recommendations (see http://tinyurl.com/ m94wqk). National regulatory authorities could help by banning monotherapies, says Bosman, but many are weak, understaffed and lack expertise. "It's terrible," says Bosman, adding that every country where malaria is endemic is affected by the problem. "Who says there is no profit to be made in malaria? When you see the number of companies operating in Africa, and the diversity of products, you'd just be amazed."
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Argentines have been travelling abroad to buy flu drugs.
